Table 2 Second-line chemotherapy which eligible patients received and tumor response evaluated RECIST ver1.1
Regimen | BBP group (%) | Non-BBP group (%) |
Oxaliplatin-based | ||
 FOLFOX | 0 (0) | 1 (4.0) |
 FOLFOX+BEV | 7 (18.9) | 0 (0) |
Irinotecan-based | ||
 FOLFIRI | 0 (0) | 4 (16.0) |
 FOLFIRI+CET/PANI | 0 (0) | 8 (32.0) |
 Irinotecan | 0 (0) | 4 (16.0) |
 Irinotecan+CET/PANI | 0 (0) | 4 (16.0) |
 FOLFIRI+BEV | 26 (70.3) | 0 (0) |
 IRIS+BEV | 2 (5.4) | 0 (0) |
 XELIRI+BEV | 1 (2.7) | 0 (0) |
 FOLFIRI+RAM | 1 (2.7) | 0 (0) |
EGFR antibody alone | ||
 CET/PANI | 0 (0) | 4 (16.0) |
Tumor response | ||
Best response | BBP groupa (%) N = 35 | Non-BBP groupa (%) N = 22 |
 Complete response | 0 (0) | 0 (0) |
 Partial response | 3 (8.6) | 2 (9.1) |
 Stable disease | 15 (42.9) | 6 (27.3) |
 Progressive disease | 14 (40.0) | 12 (54.5) |
 Not evaluated | 3 (8.6) | 2 (9.1) |
 Objective response rate | 3 (8.6) | 2 (9.1) |
 Disease control rate | 18 (51.4) | 8 (36.4) |